Sai Life Sciences inks strategic agreement to set up Schrödinger's first dedicated offshore Research Laboratories in India
PR99425
HYDERABAD, India, Jan. 10, 2023 /PRNewswire=KYODO JBN/ --
Sai Life Sciences, one of India's fastest growing global Contract Research,
Development & Manufacturing Organisations [
https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=schrodinger-offshore-research-lab
] (CRO-CDMO), today announced that it has entered a 5-year strategic agreement
with Schrödinger, whose physics-based computational platform is transforming
the way therapeutics and materials are discovered, to set up the Sai
Schrödinger Research Laboratories (SSRL) in Hyderabad, India.
Being built inside Sai Life Sciences' R&D campus in genome valley,
Hyderabad, SSRL will be a dedicated facility for integrated discovery work
streams including medicinal & synthetic chemistry [
], in vitro biology [
], and process chemistry [
]. It will access other Sai capabilities such as in vitro ADME [
] and in vivo PK [
] as needed. The relationship will support advancement of programs that
leverage Schrödinger's validated computational platform.
Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai
Life Sciences, said, "We're truly delighted that Schrödinger has decided to
partner with Sai Life Sciences to set-up their first offshore research
laboratories. In many ways, this is a testimony to the advances we have made in
the scale, scope and depth of our integrated drug discovery [
] capabilities. We are very excited about working with the Schrödinger team
and, guided by our brand promise, will strive to make it better together."
Scheduled to open in April 2023, SSRL will commence with about 75 staff
members, across full-time-equivalents (FTEs) in Medicinal Chemistry, Biology,
Process Chemistry, Analytical Chemistry, and other support staff. Recruitment
has commenced for SSRL, and the open positions can be viewed here [
].
The Discovery business [
] of Sai Life Sciences has been witnessing a transformative phase of growth in
recent years, as is evidenced in its expanding client mix and diversity of
programs. Powered by investments in talent, technology and capacity across
Boston and Hyderabad, the company's global delivery model is delivering unique
value to its customers through an optimal blend of talent, speed, and cost
efficiency. This journey typically starts with its exploratory biology facility
[
] in Boston, where the company works hand-in-hand with clients in real-time on
early discovery biology programs that are difficult to outsource. These
programs then transition to the company's Hyderabad R&D campus [
], where it has consolidated its chemistry, biology and ADME-PK services in one
integrated campus, allowing Sai scientists to work as teams and deliver quality
data to its customers.
About Sai Life Sciences
Sai Life Sciences is a full-service CRO-CDMO [
https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=schrodinger-offshore-research-lab
] that works with innovator pharma and biotech companies globally, to
accelerate the discovery, development and commercialisation of small molecules.
It takes a nimble and creative approach to deliver high-quality, cost-effective
solutions for its clients that accelerate their time to market. Backed by
global investors, TPG Capital and HBM Healthcare Investments, the company today
works with over 200 innovator companies globally and has over 2500 employees
across its facilities in India, UK and USA. https://www.sailife.com/
Photo: https://mma.prnewswire.com/media/1980494/SSRL_India.jpg
Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg
Source: Sai Life Sciences
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
